ARGENX SE

Argenx’s Phase 3 success for efgartigimod (ALKIVIA) shows early, sustained benefit in autoimmune myositis, promising a high‑value, rare‑disease biologic despite manufacturing and pricing hurdles.

European markets dipped as Argenx fell, spotlighting biotech patent cliffs and payer pressure, while SAP’s cloud & AI focus shows tech resilience amid investor caution.

Argenx’s acquisition of Forte Biosciences boosts its autoimmune pipeline with the promising CD122 antibody FB102, offering a novel cytokine‑receptor approach to treat vitiligo and coeliac disease.

Argenx’s $2.2 billion cash acquisition of Forte Biosciences adds the promising anti‑CD122 antibody FB102 to its autoimmune portfolio, boosting growth, payer value, and market position.

Argenx’s FcRn‑targeted biologic Vyvgart offers a precision approach to autoimmune disease, spotlighting its market potential, regulatory hurdles, and competitive edge.

Argenx & Halozyme reshape advanced therapeutics: high‑margin biologics meet delivery tech, boosting value‑based pricing and investor confidence.

Argenx’s AI‑powered portfolio tools at Exchange26 EMEA show 10 pp gains in success rates and €27 M ROI, while Sanofi’s Phase III withdrawal warns of high clinical‑risk costs.

Argenx’s June 2026 investor events highlight its FcRn‑blocker efgartigimod, detailing clinical progress, pricing strategy, and a $310 M revenue outlook for severe autoimmune therapy.

Janus Henderson’s Global Sustainable Equity Active ETF outperformed MSCI World in April 2026 by leveraging AI‑driven tech gains, underweighting weak energy and staples, and positioning for long‑term renewable growth.

Argenx SE’s earnings prompt revised analyst targets amid leadership shifts: solid 12% revenue growth, 28% margin, €115m cash flow, yet cautious valuations reflect market uncertainty yet strong pipeline optimism.